Counterpoint Mutual Funds LLC Purchases Shares of 51,658 10x Genomics, Inc. (NASDAQ:TXG)

Counterpoint Mutual Funds LLC acquired a new position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 51,658 shares of the company's stock, valued at approximately $742,000.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in 10x Genomics by 355.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock worth $8,027,000 after acquiring an additional 277,355 shares in the last quarter. Entropy Technologies LP boosted its holdings in 10x Genomics by 285.6% in the 4th quarter. Entropy Technologies LP now owns 37,595 shares of the company's stock worth $540,000 after buying an additional 27,844 shares during the last quarter. Geode Capital Management LLC increased its stake in 10x Genomics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company's stock worth $41,009,000 after buying an additional 42,777 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of 10x Genomics by 209.8% during the fourth quarter. SG Americas Securities LLC now owns 73,046 shares of the company's stock valued at $1,049,000 after acquiring an additional 49,468 shares during the last quarter. Finally, Alberta Investment Management Corp purchased a new position in shares of 10x Genomics in the fourth quarter valued at approximately $3,206,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,573 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the sale, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. This represents a 1.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Alan Mateo acquired 40,000 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was bought at an average price of $11.14 per share, with a total value of $445,600.00. Following the purchase, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their position. The disclosure for this purchase can be found here. Insiders own 10.03% of the company's stock.

Remove Ads

10x Genomics Trading Up 4.4 %

TXG traded up $0.44 during mid-day trading on Friday, hitting $10.39. 3,433,644 shares of the stock were exchanged, compared to its average volume of 2,001,462. The firm's fifty day moving average is $12.79 and its two-hundred day moving average is $15.67. 10x Genomics, Inc. has a 1-year low of $9.27 and a 1-year high of $39.30. The company has a market cap of $1.27 billion, a PE ratio of -6.84 and a beta of 1.93.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, research analysts anticipate that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Morgan Stanley lowered their target price on shares of 10x Genomics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. JPMorgan Chase & Co. lowered their target price on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, February 13th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a report on Friday, March 7th. Barclays lowered their price objective on 10x Genomics from $19.00 to $18.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Finally, Stifel Nicolaus cut their target price on 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $20.21.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.